Five-year efficacy and safety of tildrakizumab in patients with moderate to severe psoriasis who respond at week 28: pooled analyses of two randomised phase 3 clinical trials (reSURFACE 1 and reSURFACE 2)

Authors :: Thaçi, D
Piaserico, S
Warren, R B
Gupta, A K
Cantrell, W
Draelos, Z
Foley, P
Igarashi, A
Langley, R G
Asahina, A
Young, M
Falqués, M
Pau-Charles, I
Mendelsohn, A M
Rozzo, S J
Reich, K
Publication Year :: 2021

Tools